炎症性脉络膜新生血管接受玻璃体腔抗血管内皮生长因子治疗二十四个月结局:两种治疗方案比较
本研究比较炎症性脉络膜新生血管眼接受玻璃体腔抗血管内皮生长因子注射的两种方案24个月结局:LOADING组先3次每月负荷注射后按需再治疗,PRN组从一开始即按需治疗。共纳入82眼(LOADING组42眼、PRN组40眼)。两组视力均较基线显著提高并维持,24个月时两组视力无差异,但LOADING组注射次数显著更多,复发情况相似。
要点
- LOADING组与PRN组24个月视力分别为72.3(14.0)与74.7(11.3)字母,两组间无差异(p=0.36)。
- LOADING组注射次数中位数4.5(3-7)次,显著多于PRN组的2.5(2-3.2)次(p<0.0001)。
- 两组iCNV复发情况相似,负荷期未在结局上带来任何优势。
核心结论
- 炎症性脉络膜新生血管对抗血管内皮生长因子治疗反应良好,视力获得显著且持续的改善。
- 负荷期在结局方面未带来任何优势。
- 从一开始即采用PRN方案与更密集的治疗同样有效。
研究设计与样本
- 研究将接受玻璃体腔抗血管内皮生长因子注射治疗的炎症性脉络膜新生血管眼分为两组:LOADING组先接受3次每月注射的负荷期后按需再治疗,PRN组从一开始即按需治疗。
- 共纳入82眼,LOADING组42眼,PRN组40眼,比较两组24个月时的视力、注射次数和iCNV复发情况。
主要发现
- 基线视力(均值(SD))LOADING组为57.3(15.8)字母,PRN组为60.7(15.6)字母(p=0.32)。
- 3个月时视力(均值(95%CI))LOADING组增加+14.8(10.6至18.9)字母,PRN组增加+11.2(6.4至16)字母。
- 两组视力在整个随访期间均持续显著高于基线(所有p<0.001)。
- 24个月时LOADING组与PRN组视力分别为72.3(14.0)与74.7(11.3)字母,两组间无差异(p=0.36)。
- LOADING组注射次数中位数(Q1-Q3)为4.5(3-7)次,显著多于PRN组的2.5(2-3.2)次(p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIM: There is still no established treatment regimen for eyes with inflammatory choroidal neovascularisation (iCNV) treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections. This study compared the 24-month outcomes of two treatment regimens of anti-VEGF injections in eyes with iCNV. METHODS: Eyes with iCNV treated with anti-VEGF injections were divided into two groups: eyes treated with a loading phase of 3 monthly injections and then re-treated as needed (LOADING group) and eyes treated as needed from the beginning (PRN group). Visual acuity (VA), number of injections and iCNV recurrences at 24 months were compared between the groups. RESULTS: Eighty-two eyes were included, 42 in the LOADING and 40 in the PRN group. Baseline VA (mean(SD)) was 57.3 (15.8) letters in the LOADING vs 60.7 (15.6) letters in the PRN group (p=0.32). The VA (mean (95% CI)) increased at 3 months (+14.8 (10.6 to 18.9) and +11.2 (6.4 to 16) letters in the LOADING and PRN group, respectively) and remained significantly higher than baseline over the entire follow-up in both groups (all p<0.001). At 24 months, there was no difference in VA between the LOADING and PRN group (72.3 (14.0) vs 74.7 (11.3) letters, p=0.36) but the LOADING group received significantly more injections (median (Q1-Q3)) than the PRN (4.5 (3-7) vs 2.5 (2-3.2), p<0.0001). The iCNV recurrences were similar in both groups. CONCLUSIONS: iCNV responded well to anti-VEGF with significant and sustained VA improvement. The loading phase did not confer any advantage in terms of outcomes. PRN regimen from the beginning was as effective as more intensive treatment.
引用
- Invernizzi A, Pichi F, Symes R, et al. Twenty-four-month outcomes of inflammatory choroidal neovascularisation treated with intravitreal anti-vascular endothelial growth factors: a comparison between two treatment regimens. Br J Ophthalmol. 2019. PMID: 31744798. doi:10.1136/bjophthalmol-2019-315257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。